Processa Pharmaceuticals, Inc. Payments of Debt Issuance Costs
Processa Pharmaceuticals, Inc. (PCSA) reported Payments of Debt Issuance Costs of $2.81 thousand for the 3-month period ending 2020-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2021-05-13
- Processa Pharmaceuticals, Inc. payments of debt issuance costs for the quarter ending 2020-03-31 was $2.81K.
- Processa Pharmaceuticals, Inc. payments of debt issuance costs for the quarter ending 2018-12-31 was $77.76K, a 2.56% decline year-over-year.
- Processa Pharmaceuticals, Inc. payments of debt issuance costs for the quarter ending 2017-12-31 was $79.80K.
- Processa Pharmaceuticals, Inc. payments of debt issuance costs for fiscal 2019 was $4.28K, a 94.81% decline from fiscal 2018.
- Processa Pharmaceuticals, Inc. payments of debt issuance costs for fiscal 2018 was $82.50K, a 46.70% decline from fiscal 2017.
- Processa Pharmaceuticals, Inc. payments of debt issuance costs for fiscal 2017 was $154.80K.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|
| 2020-03-31 | $2.81K 10-Q · filed 2021-05-13 | ||
| 2019-12-31 | $4.28K 10-K · filed 2021-03-25 | ||
| 2018-12-31 | $77.76K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | $82.50K 10-K · filed 2020-03-06 | |
| 2018-09-30 | $4.74K 10-Q · filed 2019-11-14 | ||
| 2017-12-31 | $79.80K derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-04-08 | $154.80K 10-K/A · filed 2019-04-08 | |
| 2017-09-30 | $75.00K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |